BACKGROUND: National guidelines recommend the use of secondary prevention modalities for patients with peripheral artery disease (PAD) and coronary artery disease. The effect of prior PAD on the treatment and outcomes of patients with acute coronary syndromes (ACS), however, is not well characterized. The objectives of this study were to assess treatment practices and hospital outcomes in patients with ACS and prior PAD. METHODS: Data were analyzed from 41,108 patients aged > or =18 years with ACS and enrolled in the large multinational GRACE between 1999 and 2004. RESULTS: Of the 41,108 patients, 4003 (9.7%) had prior PAD. Patients with PAD were older, more likely to be men, to have a variety of prior comorbidities, and to present with non-ST-segment elevation myocardial infarction and a higher Killip class than patients without PAD. Patients with PAD were less likely to be treated with effective cardiac medications than patients without PAD. At the time of hospital presentation, patients with prior PAD had low rates of use of beneficial cardiac medications, including angiotensin-converting enzyme inhibitors, aspirin, beta-blockers, and lipid-lowering agents. Patients with PAD were significantly more likely to experience the composite hospital end point (death, shock, recurrent angina, stroke) than patients without prior PAD (adjusted OR 1.17; 95% CI 1.08-1.26). CONCLUSIONS: Patients with prior PAD received less aggressive treatment with proven cardiac medications during hospitalization for an ACS than patients without PAD. Utilization of beneficial medical therapies in patients with PAD before hospitalization with ACS was also less than optimal. Given the poorer hospital outcomes in patients with PAD, our findings suggest considerable opportunity to improve care for these high-risk patients.
BACKGROUND: National guidelines recommend the use of secondary prevention modalities for patients with peripheral artery disease (PAD) and coronary artery disease. The effect of prior PAD on the treatment and outcomes of patients with acute coronary syndromes (ACS), however, is not well characterized. The objectives of this study were to assess treatment practices and hospital outcomes in patients with ACS and prior PAD. METHODS: Data were analyzed from 41,108 patients aged > or =18 years with ACS and enrolled in the large multinational GRACE between 1999 and 2004. RESULTS: Of the 41,108 patients, 4003 (9.7%) had prior PAD. Patients with PAD were older, more likely to be men, to have a variety of prior comorbidities, and to present with non-ST-segment elevation myocardial infarction and a higher Killip class than patients without PAD. Patients with PAD were less likely to be treated with effective cardiac medications than patients without PAD. At the time of hospital presentation, patients with prior PAD had low rates of use of beneficial cardiac medications, including angiotensin-converting enzyme inhibitors, aspirin, beta-blockers, and lipid-lowering agents. Patients with PAD were significantly more likely to experience the composite hospital end point (death, shock, recurrent angina, stroke) than patients without prior PAD (adjusted OR 1.17; 95% CI 1.08-1.26). CONCLUSIONS:Patients with prior PAD received less aggressive treatment with proven cardiac medications during hospitalization for an ACS than patients without PAD. Utilization of beneficial medical therapies in patients with PAD before hospitalization with ACS was also less than optimal. Given the poorer hospital outcomes in patients with PAD, our findings suggest considerable opportunity to improve care for these high-risk patients.
Authors: Ibrahim Al-Zakwani; Ekram Al Siyabi; Najib Alrawahi; Arif Al-Mulla; Abdullah Alnaeemi; Abdulla Shehab; Mohammad Zubaid Journal: Med Princ Pract Date: 2019-02-10 Impact factor: 1.927
Authors: Amanda M Rushing; Erminia Donnarumma; David J Polhemus; Kevin R Au; Samuel E Victoria; Jeffrey D Schumacher; Zhen Li; J Stephen Jenkins; David J Lefer; Traci T Goodchild Journal: J Vasc Surg Date: 2019-02-15 Impact factor: 4.268
Authors: Sumeet Subherwal; Deepak L Bhatt; Shuang Li; Tracy Y Wang; Laine Thomas; Karen P Alexander; Manesh R Patel; E Magnus Ohman; W Brian Gibler; Eric D Peterson; Matthew T Roe Journal: Circ Cardiovasc Qual Outcomes Date: 2012-06-19
Authors: Jessica M Bradley; Kazi N Islam; David J Polhemus; Erminia Donnarumma; Luke P Brewster; Ya-Xiong Tao; Traci T Goodchild; David J Lefer Journal: Am J Physiol Heart Circ Physiol Date: 2015-05-08 Impact factor: 4.733
Authors: Dirk De Bacquer; Delphine De Smedt; Kornelia Kotseva; Catriona Jennings; David Wood; Lars Rydén; Viveca Gyberg; Bahira Shahim; Philippe Amouyel; Jan Bruthans; Almudena Castro Conde; Renata Cífková; Jaap W Deckers; Johan De Sutter; Mirza Dilic; Maryna Dolzhenko; Andrejs Erglis; Zlatko Fras; Dan Gaita; Nina Gotcheva; John Goudevenos; Peter Heuschmann; Aleksandras Laucevicius; Seppo Lehto; Dragan Lovic; Davor Miličić; David Moore; Evagoras Nicolaides; Raphael Oganov; Andrzej Pajak; Nana Pogosova; Zeljko Reiner; Martin Stagmo; Stefan Störk; Lale Tokgözoğlu; Dusko Vulic; Martin Wagner; Guy De Backer Journal: Eur J Epidemiol Date: 2018-10-23 Impact factor: 8.082
Authors: Erik Biros; Gabor Gäbel; Corey S Moran; Charlotte Schreurs; Jan H N Lindeman; Philip J Walker; Maria Nataatmadja; Malcolm West; Lesca M Holdt; Irene Hinterseher; Christian Pilarsky; Jonathan Golledge Journal: Oncotarget Date: 2015-05-30